english.prescrire.org > Spotlight > 100 most recent > Mavacamten (Camzyos°) in hypertrophic cardiomyopathy?

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Mavacamten (Camzyos°) in hypertrophic cardiomyopathy?

 Marketing Authorisations  Mavacamten, described as a selective and reversible inhibitor of cardiac myosin, has been authorised in the European Union in the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults. Does it extend survival in this situation, alleviate the symptoms of the disease (especially compared with a beta blocker or a calcium-channel blocker), reduce the incidence of serious complications, and avert the need for heart surgery? And what are its adverse effects?
Full article (3 pages) available for download by subscribers

 ©Prescrire 1 February 2025

Source: "Mavacamten (Camzyos°) in hypertrophic cardiomyopathy" Prescrire Int 2025; 34 (267): 33-36. Subscribers only.

Filet

Enjoy full access to Prescrire International, and support independent information